Clinical Trial Update: Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial update evaluating either docetaxel plus cetuximab or adding atezolizumab to standard chemotherapy and radiation for high-risk head an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Cetuximab (cetuximab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Phase 2, Phase 3 | Status: RECRUITING